ASND Company Profile and Key Details

Q: Who are the executives of ASND?

Mr. Jan Moller MikkelsenPres, Chief Executive Officer, Member of Executive Board & Exec. DirectorDr. Kennett SprogoeSenior Vice President and Head of Innovation & ResearchMr. Peter RasmussenVice President of Fin. & Principal Accounting OfficerMr. Timothy J. LeeSenior Director of Investor RelationsMr. Scott T. SmithChief Financial Officer, Executive Vice President & Member of Exec. BoardMs. Lotte SonderbjergExecutive Vice President, Chief Admin. Officer & Member of the Exec. BoardMr. Flemming Steen JensenExecutive Vice President of Product Supply & Quality - Endocrinology Rare DiseasesDr. Jens Sigurd Okkels Ph.D.Executive Vice President of Product Devel.Dr. Birgitte Volck M.D., Ph.D.Executive Vice President and Head of Clinical Devel. & Medical Affairs - Endocrinology Rare DiseasesDr. Kennett Sprogoe Ph.D.Executive Vice President and Head of Innovation & ResearchMr. Michael Wolff Jensen L.L.M.Executive Vice President, Chief Legal Officer & Member of the Exec. Board

NASDAQ : ASND

Ascendis Pharma A/S

$260.05

0.428+0.16%

Open: 9:58 AM

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Ascendis Pharma A/S (ASND) stock surged +0.16%, trading at $260.05 on NASDAQ, up from the previous close of $259.62. The stock opened at $256.65, fluctuating between $256.65 and $260.98 in the recent session.

Stock Snapshot

259.62

Prev. Close

16.15B

Market Cap

256.65

Day Low

-107.46

P/E Ratio

-2.42

EPS (TTM)

-8.3

Cash Flow per Share

256.65

Open

62.11M

Number of Shares

260.98001

Day High

99.22%

Free Float in %

-2.57

Book Value

55.27K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Aug 19, 2026	255.00	261.61	251.11	259.62	541.21K
Aug 18, 2026	246.47	253.55	245.68	248.85	452.63K
Aug 17, 2026	246.33	250.62	242.00	247.40	554.1K
Aug 14, 2026	243.63	249.52	240.64	248.50	650.36K
Aug 13, 2026	250.38	251.43	244.12	246.23	1.06M
Aug 12, 2026	253.92	258.55	251.92	255.46	434.52K
Aug 11, 2026	256.70	258.48	252.26	254.57	418.49K
Aug 10, 2026	255.01	257.42	251.00	255.62	423.47K
Aug 07, 2026	251.76	257.57	251.76	255.41	325.55K
Aug 06, 2026	244.70	254.98	244.70	249.85	629.76K
Aug 05, 2026	246.64	249.50	243.57	244.20	453.2K
Aug 04, 2026	245.90	247.98	239.56	244.59	791.83K
Aug 03, 2026	244.68	245.66	239.93	243.45	622.95K
Jul 31, 2026	249.71	252.46	243.30	243.91	508.88K
Jul 30, 2026	250.00	253.07	245.84	251.07	465.68K
Jul 29, 2026	254.94	260.22	251.66	252.05	507.08K
Jul 28, 2026	255.53	255.53	246.62	254.44	574.82K
Jul 27, 2026	255.56	258.58	252.93	253.42	365.41K
Jul 24, 2026	254.40	258.86	251.99	253.86	390.36K
Jul 23, 2026	251.55	256.09	249.99	252.66	293.45K

Contact Details

Hellerup, CR 2900

Denmark

https://ascendispharma.com 457 022 2244

About Company

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.

Stock Peers

ARGX

39.87+4.02%

argenx SE$1,032.86 REGN

30.6+3.78%

Regeneron Pharmaceuticals, Inc.$840.84 VRTX

23.87+4.52%

Vertex Pharmaceuticals Incorporated$552.06 MDGL

15.79+3.01%

Madrigal Pharmaceuticals, Inc.$540.16 UTHR

10.87+2.10%

United Therapeutics Corporation$529.14 PRAX

16.35+4.42%

Praxis Precision Medicines, Inc.$386.19 ONC

7.71+2.09%

BeOne Medicines AG$376.86 KRYS

10.52+3.16%

Krystal Biotech, Inc.$343.34 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

3.12+1.08%

Ligand Pharmaceuticals Incorporated$290.71

Frequently Asked Questions

What is the current Ascendis Pharma A/S (ASND) stock price?

Ascendis Pharma A/S (NASDAQ: ASND) stock price is $260.05 in the last trading session. During the trading session, ASND stock reached the peak price of $260.98 while $256.65 was the lowest point it dropped to. The percentage change in ASND stock occurred in the recent session was 0.16% while the dollar amount for the price change in ASND stock was $0.43.

ASND's industry and sector of operation?

The NASDAQ listed ASND is part of Biotechnology industry that operates in the broader Healthcare sector. Ascendis Pharma A/S designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ASND?

Mr. Jan Moller Mikkelsen
Pres, Chief Executive Officer, Member of Executive Board & Exec. Director
Dr. Kennett Sprogoe
Senior Vice President and Head of Innovation & Research
Mr. Peter Rasmussen
Vice President of Fin. & Principal Accounting Officer
Mr. Timothy J. Lee
Senior Director of Investor Relations
Mr. Scott T. Smith
Chief Financial Officer, Executive Vice President & Member of Exec. Board
Ms. Lotte Sonderbjerg
Executive Vice President, Chief Admin. Officer & Member of the Exec. Board
Mr. Flemming Steen Jensen
Executive Vice President of Product Supply & Quality - Endocrinology Rare Diseases
Dr. Jens Sigurd Okkels Ph.D.
Executive Vice President of Product Devel.
Dr. Birgitte Volck M.D., Ph.D.
Executive Vice President and Head of Clinical Devel. & Medical Affairs - Endocrinology Rare Diseases
Dr. Kennett Sprogoe Ph.D.
Executive Vice President and Head of Innovation & Research
Mr. Michael Wolff Jensen L.L.M.
Executive Vice President, Chief Legal Officer & Member of the Exec. Board

How ASND did perform over past 52-week?

ASND's closing price is 39.54% higher than its 52-week low of $186.05 where as its distance from 52-week high of $282.15 is -7.99%.

How many employees does ASND have?

Number of ASND employees currently stands at 1,189.

Link for ASND official website?

Official Website of ASND is: https://ascendispharma.com

How do I contact ASND?

ASND could be contacted at phone 457 022 2244 and can also be accessed through its website. ASND operates from Tuborg Boulevard 12, Hellerup, CR 2900, Denmark.

How many shares of ASND are traded daily?

ASND stock volume for the day was 55.27K shares. The average number of ASND shares traded daily for last 3 months was 677.87K.

What is the market cap of ASND currently?

The market value of ASND currently stands at $16.15B with its latest stock price at $260.05 and 62.11M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	1189
Beta	0.38
Sales or Revenue	$266.72M
5Y Sales Change%	17.399%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	1189
Beta	0.38
Sales or Revenue	$266.72M
5Y Sales Change%	17.399%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ASND Company Profile and Key Details

Ascendis Pharma A/S

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook